trending Market Intelligence /marketintelligence/en/news-insights/trending/0_fob5z4o6imbmf00asqpq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Cynata stem cell therapy gets US orphan drug status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cynata stem cell therapy gets US orphan drug status

The U.S. Food and Drug Administration granted orphan drug status to Cynata Therapeutics Ltd.'s stem cell therapy CYP-001.

The drug is meant to treat the acute graft versus host disease, which occurs after transplant procedures when immune cells from transplanted tissue attack the recipient. The disease has a high mortality rate.

The orphan drug status will help expedite development of CYP-001 and entitles Cynata to seven years of exclusive market rights and tax credits once the treatment is commercialized.

CYP-001 is being studied in an early stage trial.